Stacey Kowal
YOU?
Author Swipe
View article: Estimating the societal economic burden of food allergy in the United States
Estimating the societal economic burden of food allergy in the United States Open
Using a population cost exercise that incorporated a range of epidemiologically plausible explanations, we estimated the annual total societal cost of FA in the US may approach $370.8 billion, mostly from indirect costs borne by patients/c…
View article: Two Approaches for Measuring Treatment Value Under Uncertainty: Estimating Insurance Value and Risk Preferences in Neurology
Two Approaches for Measuring Treatment Value Under Uncertainty: Estimating Insurance Value and Risk Preferences in Neurology Open
Neurological conditions adversely impact patients and society due to both quality-of-life decrements and high financial burden. Traditional cost effectiveness methods, however, may undervalue neurological treatments by assuming patients ar…
View article: Validating the Social Vulnerability Index for alternative geographies in the United States to explore trends in social determinants of health over time and geographic location
Validating the Social Vulnerability Index for alternative geographies in the United States to explore trends in social determinants of health over time and geographic location Open
Objective To create county-, 5-digit ZIP code (ZIP-5)–, and 3-digit ZIP code (ZIP-3)–level datasets of the Social Vulnerability Index (SVI) and its components for 2016–2022 to validate the methodology beyond county level, explore trends in…
View article: Assessing treatment value under uncertainty: Measuring treatment value for a new treatment for cognitive impairment
Assessing treatment value under uncertainty: Measuring treatment value for a new treatment for cognitive impairment Open
Background The value payers and policymakers traditionally place on novel treatments for Alzheimer’s and other neurological diseases that cause cognitive impairment (CI) and dementia often ignores disease baseline severity. More patient‐ce…
View article: Modeling the Population Equity of Alzheimer Disease Treatments in the US
Modeling the Population Equity of Alzheimer Disease Treatments in the US Open
Importance The arrival of new medications for Alzheimer disease (AD) has prompted efforts to measure their value using conventional cost-effectiveness analyses; however, these analyses focus on how much health improvement new medications g…
View article: The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis Open
View article: Living with and Caring for People with Multiple Food Allergies: A Qualitative Study
Living with and Caring for People with Multiple Food Allergies: A Qualitative Study Open
These findings highlight that people with multiple food allergies experience social limitations, stress about food safety and allergen avoidance, and restrictions on freedom. Caregiver QoL is impacted by the need to navigate social, emotio…
View article: Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment
Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment Open
The inconsistent inclusion of family spillover effects in HTAs and CEAs remains a persistent challenge. The stakeholder-driven recommendations and research opportunities identified in this study may help improve the transparency, measureme…
View article: The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations Open
Aim: We investigated the effect of shortening time between innovations with the accelerated approval (AA) pathway on patient outcomes for three solid tumors. Methods: This real-world analysis evaluated patients receiving sequ…
View article: Assessing the impact of grief on quality of life, work productivity, and health outcomes for parents bereaved from SMA: A study protocol
Assessing the impact of grief on quality of life, work productivity, and health outcomes for parents bereaved from SMA: A study protocol Open
Background U.S. cost-effectiveness recommendations suggest that analyses should include all costs and effects relevant to the decision problem [1]. However, in many diseases, including spinal muscular atrophy (SMA), few studies have evalua…
View article: Estimating the US Baseline Distribution of Health Inequalities Across Race, Ethnicity, and Geography for Equity-Informative Cost-Effectiveness Analysis
Estimating the US Baseline Distribution of Health Inequalities Across Race, Ethnicity, and Geography for Equity-Informative Cost-Effectiveness Analysis Open
View article: Table of Contents
Table of Contents Open
View article: OP67 Considerations Of Treatment Novelty In Health Technology Assessment
OP67 Considerations Of Treatment Novelty In Health Technology Assessment Open
Introduction A recent proliferation of value frameworks, as well as the emergence of innovative approaches to treating disease (e.g., cell/gene therapies) have been accompanied by an increased focus on nontraditional elements of value. We …
View article: The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis
The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis Open
View article: When are breakthrough therapies cost-effective?
When are breakthrough therapies cost-effective? Open
BACKGROUND: An increasing proportion of novel drug approvals use accelerated pathways, with notable growth in the US Food and Drug Administration-designated breakthrough pathway in recent years. Breakthrough therapy (BT) designation…
View article: A Pragmatic Guide to Assessing Real Option Value for Medical Technologies
A Pragmatic Guide to Assessing Real Option Value for Medical Technologies Open
View article: Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer Open
View article: A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States
A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States Open
Effective COVID-19 treatments for hospitalized patients may not only reduce disease burden but also represent good value for the health system and society. Though data limitations remain, this cost-effectiveness framework expands beyond cu…
View article: A cost–benefit analysis of smoking cessation prescription coverage from a US payer perspective
A cost–benefit analysis of smoking cessation prescription coverage from a US payer perspective Open
Given the proven efficacy of SC pharmacotherapy, near-term investments in supporting ACA-recommended SC coverage translate into a positive ROI. As smoking is a leading cause of morbidity and mortality, increased access to prescription SC m…
View article: Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care Estimator.
Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care Estimator. Open
The use of the TCoC estimator supports population health management by providing real-world evidence benchmark data on NVAF disease burden and by quantifying the potential value of disease-management activities in shifting cost trends.
View article: The Cost-Effectiveness of Bendamustine-Rituximab (Ben-R) Versus R-Chop for the First Line Treatment of Patients with Indolent Non-Hodgkin’s Lymphoma (Inhl) in Colombia
The Cost-Effectiveness of Bendamustine-Rituximab (Ben-R) Versus R-Chop for the First Line Treatment of Patients with Indolent Non-Hodgkin’s Lymphoma (Inhl) in Colombia Open